Bloomage BioTechnology Corp Ltd reports 44.1 pp EBITDA Margin decline from 44.1% to in 2016 in 2016
22/03/2017 • About Bloomage BioTechnology Corp Ltd (
$963) • By InTwits
Bloomage BioTechnology Corp Ltd reported FY2016 financial results today. Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
Bloomage BioTechnology Corp Ltd ($963) key annual financial indicators
| mln. CNY | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 275.0 | 375.2 | 481.3 | 650.9 | 844.4 | 29.7% |
| Gross Profit | 190.6 | 299.9 | 375.4 | 487.2 | | -100.0% |
| SG&A | 77.3 | 174.7 | 178.8 | 249.0 | | -100.0% |
| EBITDA | 128.6 | 146.9 | 217.6 | 287.0 | | -100.0% |
| Net Income | 89.3 | 94.4 | 162.1 | 190.4 | 228.1 | 19.8% |
Balance Sheet
|
|---|
| Cash | 120.6 | 133.4 | 172.0 | 396.1 | | -100.0% |
| Short Term Debt | 9.2 | 45.9 | 26.5 | 484.4 | | -100.0% |
| Long Term Debt | 45.6 | 44.7 | 42.9 | 366.9 | | -100.0% |
Cash flow
|
|---|
| Capex | 98.5 | 114.1 | 118.4 | 267.0 | | -100.0% |
Ratios
|
|---|
| Revenue growth | 33.4% | 36.4% | 28.3% | 35.2% | 29.7% | |
| EBITDA growth | 11.0% | 14.3% | 48.1% | 31.9% | | |
| Gross Margin | 69.3% | 79.9% | 78.0% | 74.9% | | -74.9% |
| EBITDA Margin | 46.8% | 39.2% | 45.2% | 44.1% | 0.0% | -44.1% |
| Net Income Margin | 32.5% | 25.2% | 33.7% | 29.3% | 27.0% | -2.2% |
| SG&A, % of revenue | 28.1% | 46.6% | 37.1% | 38.3% | | -38.3% |
| CAPEX, % of revenue | 35.8% | 30.4% | 24.6% | 41.0% | | -41.0% |
| ROIC | 30.1% | 24.1% | 27.2% | 17.1% | | -17.1% |
| ROE | 26.8% | 20.1% | 24.6% | 19.6% | | -19.6% |
| Net Debt/EBITDA | -0.5x | -0.3x | -0.5x | 1.6x | | -1.6x |
Revenue and profitability
Bloomage BioTechnology Corp Ltd's Revenue surged on 29.7%.
Net Income marign decreased on 2.2 pp from 29.3% to 27.0% in FY2016.
Appendix 1: Peers in Biotechnology
Below we provide Bloomage BioTechnology Corp Ltd benchmarking against other companies in Biotechnology industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| China Regenerative Medicine International Ltd ($8158) | | 975.8% | -63.0% | 452.4% | 885.1% |
| Essex Bio-technology Ltd ($1061) | | 29.9% | 49.3% | 26.2% | 18.6% |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | | 78.9% | 13.2% | 23.1% | 7.3% |
| Uni-Bio Science Group Ltd ($690) | -25.7% | 46.1% | 23.1% | 20.2% | |
| Amgen Inc ($4332) | | 8.2% | 7.4% | 8.0% | 6.1% |
| |
|---|
| Median (8 companies) | -21.2% | 19.6% | 3.5% | 14.1% | 6.7% |
|---|
| Bloomage BioTechnology Corp Ltd ($963) | | 36.4% | 28.3% | 35.2% | 29.7% |
Top companies by Gross margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | 89.9% | 92.2% | 92.2% | 91.4% | 92.5% |
| Uni-Bio Science Group Ltd ($690) | 67.2% | 79.5% | 80.0% | 83.3% | |
| Essex Bio-technology Ltd ($1061) | 91.2% | 89.6% | 79.3% | 81.0% | 80.3% |
| Amgen Inc ($4332) | 81.5% | 82.1% | 78.0% | 80.5% | 81.9% |
| China Regenerative Medicine International Ltd ($8158) | 33.6% | -17.3% | 31.0% | 49.2% | 66.1% |
| |
|---|
| Median (8 companies) | 50.7% | 57.3% | 56.5% | 64.8% | 73.2% |
|---|
| Bloomage BioTechnology Corp Ltd ($963) | 69.3% | 79.9% | 78.0% | 74.9% | |
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Amgen Inc ($4332) | 38.6% | 38.3% | 41.3% | 48.8% | 51.8% |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | 33.4% | 29.0% | 31.5% | 29.3% | 29.8% |
| Essex Bio-technology Ltd ($1061) | 19.0% | 21.9% | 21.3% | 22.6% | 23.4% |
| CK Life Sciences International Holdings Inc ($775) | 9.9% | 10.0% | 10.7% | 11.3% | 11.2% |
| Tianjin TEDA Biomedical Engineering Co Ltd ($8189) | 6.9% | 7.4% | 9.1% | 9.2% | 6.6% |
| |
|---|
| Median (8 companies) | 8.4% | 8.7% | 9.9% | 10.3% | 17.3% |
|---|
| Bloomage BioTechnology Corp Ltd ($963) | 46.8% | 39.2% | 45.2% | 44.1% | |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| China Regenerative Medicine International Ltd ($8158) | 40,271.9% | 810.7% | 3,305.9% | 1,295.1% | 58.9% |
| Uni-Bio Science Group Ltd ($690) | 23.9% | 28.9% | 35.5% | 15.3% | |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | 49.3% | 13.6% | 9.4% | 6.6% | |
| CK Life Sciences International Holdings Inc ($775) | 3.8% | 5.8% | 9.9% | 6.0% | |
| Global Bio-Chem Technology Group Co Ltd ($809) | 17.7% | 1.7% | 3.0% | 2.8% | |
| |
|---|
| Median (8 companies) | 20.8% | 8.1% | 7.1% | 4.4% | 31.1% |
|---|
| Bloomage BioTechnology Corp Ltd ($963) | 35.8% | 30.4% | 24.6% | 41.0% | |
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Essex Bio-technology Ltd ($1061) | 22.6% | 25.2% | 28.5% | 31.4% | 30.7% |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | 20.0% | 20.9% | 18.6% | 17.6% | 16.4% |
| Amgen Inc ($4332) | 13.0% | 11.7% | 11.2% | 14.6% | 15.8% |
| Tianjin TEDA Biomedical Engineering Co Ltd ($8189) | 12.4% | 10.1% | 9.8% | 9.5% | 4.3% |
| CK Life Sciences International Holdings Inc ($775) | 4.2% | 4.1% | 4.3% | 4.8% | 4.7% |
| |
|---|
| Median (8 companies) | 8.3% | 7.1% | 7.0% | 7.2% | 10.3% |
|---|
| Bloomage BioTechnology Corp Ltd ($963) | 30.1% | 24.1% | 27.2% | 17.1% | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| CK Life Sciences International Holdings Inc ($775) | 4.3x | 6.1x | 6.4x | 6.0x | 5.8x |
| Amgen Inc ($4332) | 3.5x | 4.0x | 3.3x | 2.6x | 2.6x |
| Essex Bio-technology Ltd ($1061) | 0.3x | -0.0x | -0.1x | -0.1x | -0.6x |
| Tianjin TEDA Biomedical Engineering Co Ltd ($8189) | 2.0x | 1.4x | 0.9x | -1.3x | -1.8x |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ($1349) | -0.4x | -2.4x | -2.2x | -1.9x | -2.1x |
| |
|---|
| Median (5 companies) | 2.7x | 1.4x | 0.9x | -0.1x | -0.6x |
|---|
